CY1113784T1 - Φαρμακευτικη συνθεση για την θεραπεια διαβητικων επιπλοκων - Google Patents

Φαρμακευτικη συνθεση για την θεραπεια διαβητικων επιπλοκων

Info

Publication number
CY1113784T1
CY1113784T1 CY20131100211T CY131100211T CY1113784T1 CY 1113784 T1 CY1113784 T1 CY 1113784T1 CY 20131100211 T CY20131100211 T CY 20131100211T CY 131100211 T CY131100211 T CY 131100211T CY 1113784 T1 CY1113784 T1 CY 1113784T1
Authority
CY
Cyprus
Prior art keywords
diabetic
treatment
diabetic complications
present
beta
Prior art date
Application number
CY20131100211T
Other languages
English (en)
Inventor
Supreet K Deshpande
Sudhir A Kulkarni
Reena R Gollapudy
Original Assignee
Vlife Sciences Technologies Pvt Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlife Sciences Technologies Pvt Ltd. filed Critical Vlife Sciences Technologies Pvt Ltd.
Publication of CY1113784T1 publication Critical patent/CY1113784T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Κοινοποιείται μία μέθοδος για την θεραπεία διαβητικών επιπλοκών με την χορήγηση ενός βήτα αναστολέα. Οι διαβητικές επιπλοκές προκύπτουν από διαβήτες και έχουν λίγες ή καθόλου επιλογές θεραπείας. Η παρούσα εφεύρεση περιγράφει την χρήση των βήτα- αναστολέων στην θεραπεία ενός διαβητικού. Η παρούσα εφεύρεση περιγράφει επίσης την καταστολή της aldose reductase, ενός από τους κύριους αιτιολογικούς παράγοντες των διαβητικών επιπλοκών. Παρέχονται επίσης μέθοδοι της θεραπείας των διαβητικών τραυμάτων. Κοινοποιούνται συνθέσεις για την θεραπεία διαβητικών επιπλοκών όπως διαβητικά τραύματα. Η παρούσα εφεύρεση χρησιμοποιεί μια τοπική σύνθεση ενός βήτα-αναστολέα, που δεν έχει ουσιαστικά αντί-βακτηριδιακή δραστικότητα, για την βελτίωση της διαδικασίας της θεραπείας διαβητικού τραύματος. Η παρούσα εφεύρεση περιλαμβάνει επίσης αύξηση του ρυθμού συσσώρευσης κολλαγόνου για την θεραπεία του επιθηλιακού ιστού στο τραύμα ενός διαβητικού ατόμου.
CY20131100211T 2007-01-29 2013-03-08 Φαρμακευτικη συνθεση για την θεραπεια διαβητικων επιπλοκων CY1113784T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1960MU2006 2007-01-29
EP08720107.5A EP2114386B9 (en) 2007-01-29 2008-01-24 Pharmaceutical composition for treatment of diabetic complications

Publications (1)

Publication Number Publication Date
CY1113784T1 true CY1113784T1 (el) 2016-07-27

Family

ID=47263792

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100211T CY1113784T1 (el) 2007-01-29 2013-03-08 Φαρμακευτικη συνθεση για την θεραπεια διαβητικων επιπλοκων

Country Status (11)

Country Link
US (1) US8686051B2 (el)
EP (2) EP2444077A1 (el)
JP (1) JP5240586B2 (el)
CN (2) CN101616662B (el)
CA (1) CA2680843C (el)
CY (1) CY1113784T1 (el)
DK (1) DK2114386T3 (el)
ES (1) ES2400004T3 (el)
HK (2) HK1137149A1 (el)
WO (1) WO2008093356A1 (el)
ZA (1) ZA200905970B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2480204E (pt) * 2009-09-22 2014-01-22 Vlife Sciences Technologies Pvt Ltd Formulação tópica para úlceras do pé diabético
US20140356452A1 (en) * 2012-01-19 2014-12-04 Ibt Usa Inc. Therapeutic Uses of Tetrachlorodecaoxygen (TCDO)
EP2844268A4 (en) * 2012-04-20 2015-11-25 Univ Howard METHOD FOR THE TREATMENT OF EYE DISEASE AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASE
EP2968374A4 (en) * 2013-03-15 2016-08-10 Alphabet 3 Llc M METHODS AND COMPOSITIONS FOR IMPROVING OXYGEN RATE IN FABRICS
WO2015031110A2 (en) * 2013-08-27 2015-03-05 The Regents Of The University Of California Combination therapy to promote wound healing
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CN104971211A (zh) * 2014-04-02 2015-10-14 王嘉影 一种用于治疗糖尿病神经源性膀胱病的复方中药汤剂
WO2016108130A1 (en) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
CN105770860B (zh) * 2016-03-16 2021-01-05 哈尔滨医科大学 生长分化因子-11在促进糖尿病伤口愈合中的用途
EP3612225A1 (en) * 2017-04-21 2020-02-26 Steven Hoffman Compositions and methods for treating retinopathy
EP3731836B1 (en) * 2017-12-27 2023-09-20 Genepred Biotechnologies Beta-blockers for treating and/or preventing pathological scars
EP3787749A4 (en) * 2018-05-03 2022-01-26 Alimera Sciences, Inc. METHODS OF TREATMENT OF RETINAL DISEASES
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
US11154518B2 (en) * 2018-12-28 2021-10-26 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound
EP4180033A4 (en) * 2020-07-10 2024-09-25 Chang Gung Memorial Hospital Linkou USE OF ß-1 ADRENORECEPTOR ANTAGONIST FOR PREPARATION OF COMPOSITION FOR REDUCING EPITHELIAL CELL DAMAGE INDUCED BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR AND INHIBITING CANCER CELLS
CN114053419B (zh) * 2021-12-09 2023-02-24 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) 去甲肾上腺素或β-肾上腺素能受体抑制剂在制备治疗糖尿病神经修复的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL300886A (el) * 1962-11-23
US3655663A (en) * 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US4593119A (en) * 1980-11-28 1986-06-03 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
JPS58206519A (ja) 1982-05-27 1983-12-01 Kowa Co 外用β−遮断剤
US4897417A (en) 1988-12-15 1990-01-30 E. I. Du Pont De Nemours & Co. Prodrugs of 3,4-hydroxy benzoyloxypropanolamines
AU660984B2 (en) 1991-03-18 1995-07-13 Sepracor, Inc. Composition and method containing optically pure (S) metoprolol
IL143687A0 (en) 1998-12-11 2002-04-21 Khamar Bakulesh Mafatlal The process for manufacturing formulation of topical beta blockers with improved efficacy
DE60217918T2 (de) 2001-12-29 2007-11-15 Novo Nordisk A/S Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
US20100215710A1 (en) 2005-04-08 2010-08-26 The Regents Of The University Of California Beta-2 Adrenergic Receptor Agonists and Antagonists and Modulation of Wound Healing

Also Published As

Publication number Publication date
DK2114386T3 (da) 2013-03-18
CA2680843C (en) 2016-05-31
CN101616662A (zh) 2009-12-30
CA2680843A1 (en) 2008-08-07
EP2114386B1 (en) 2012-12-26
US8686051B2 (en) 2014-04-01
HK1204932A1 (en) 2015-12-11
CN101616662B (zh) 2015-07-29
JP5240586B2 (ja) 2013-07-17
ES2400004T3 (es) 2013-04-04
WO2008093356A1 (en) 2008-08-07
EP2114386B9 (en) 2013-09-18
US20110021526A1 (en) 2011-01-27
EP2114386A1 (en) 2009-11-11
HK1137149A1 (en) 2010-07-23
EP2444077A1 (en) 2012-04-25
ZA200905970B (en) 2012-08-29
CN104189906A (zh) 2014-12-10
JP2011509917A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
CY1113784T1 (el) Φαρμακευτικη συνθεση για την θεραπεια διαβητικων επιπλοκων
CU20110119A7 (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematológicas
MX343397B (es) Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
BR112012020704A2 (pt) compostos de pirrolopirimidina deuterados como inibidores de cdk4/6
EA201170650A1 (ru) Комбинация оксиданта и фотоактиватора для заживления ран
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
UA107783C2 (en) Isoindoline compounds for use in treating cancer
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
EA201001639A1 (ru) Композиции и способы их получения и применения
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
WO2010008573A3 (en) Wound healing
GB0620385D0 (en) Novel compounds
ATE539749T1 (de) Dextromethorphan für die behandlung von akne
EA201001094A1 (ru) Производные индазола
BRPI1016257B8 (pt) composições compreendendo finafloxacina para tratamento de infecções óticas
FR2978664B1 (fr) Composition antiseptique
AU2010279892A8 (en) Humanized anti-amyloid-b oligomer antibody
MY150054A (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
WO2010031708A3 (en) Ortho-aminoanilides for the treatment of cancer